Embecta Corp. (EMBC) to Issue Quarterly Dividend of $0.01 on June 15th

by · The Cerbat Gem

Embecta Corp. (NASDAQ:EMBC – Get Free Report) announced a quarterly dividend on Friday, May 1st. Stockholders of record on Thursday, May 28th will be given a dividend of 0.01 per share on Monday, June 15th. This represents a c) dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Thursday, May 28th.

Embecta has a dividend payout ratio of 1.4% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Embecta to earn $1.75 per share next year, which means the company should continue to be able to cover its $0.04 annual dividend with an expected future payout ratio of 2.3%.

Embecta Price Performance

EMBC stock opened at $3.32 on Tuesday. The company has a market cap of $196.98 million, a price-to-earnings ratio of 1.75 and a beta of 1.09. The business has a fifty day simple moving average of $7.33 and a 200-day simple moving average of $10.16. Embecta has a 52 week low of $2.77 and a 52 week high of $15.55.

Embecta (NASDAQ:EMBC – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.15). The firm had revenue of $221.80 million for the quarter, compared to analyst estimates of $235.67 million. Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The company’s quarterly revenue was down 14.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.70 earnings per share. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. As a group, analysts expect that Embecta will post 1.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on EMBC shares. Weiss Ratings downgraded Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, May 6th. Zacks Research cut shares of Embecta from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Mizuho decreased their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. BTIG Research cut shares of Embecta from a “buy” rating to a “neutral” rating in a research report on Tuesday, May 5th. Finally, Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Strong Sell” and a consensus price target of $11.00.

Read Our Latest Stock Report on Embecta

Embecta Company Profile

(Get Free Report)

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.

Read More